BioSpace News Archive

Policy

4 Biotech Companies Announce IPO Plans

Four biotech companies recently filed with the U.S. Securities and Exchange Commission their plans for initial public offerings (IPO). Let’s take a look.

April 29, 2019
·
3 min read
·
Mark Terry
Pharm Country

Merck Increases Availability of MMR Vaccine as CDC Suggests Some Adults Could Use a Booster

As the measles virus continues to run throughout the United States, Merck, the sole supplier of the MMR vaccine, said it has taken steps to increase the supply of the medication to medical facilities across the United States to help battle the outbreak.

April 29, 2019
·
2 min read
·
Alex Keown
Policy

Bay Area’s uBiome the Focus of an FBI Investigation into Billing Practices

uBiome said it “does not have any control over physician billing. Any improper billing by physicians, if it occurred, is not related to uBiome’s billing practices,”

April 29, 2019
·
2 min read
·
Alex Keown
BioCapital

Bone Abnormalities in Systemic Autoimmune Disease

An article published in Experimental Biology and Medicine details abnormalities in bone pathology that occur in systemic autoimmune disease.

April 29, 2019
·
2 min read
Business

BIO Promotes Diversity as a Key to Success in Biopharma

The Biotechnology Innovation Organization (BIO) announced on April 16 that it was implementing a program to improve gender, racial, ethnic and LGBTQ diversity on the boards of directors, executive suites and functional leadership positions in the biopharma industry.

April 29, 2019
·
5 min read
·
Mark Terry
Deals

Invitation to presentation of BioArctic’s Interim Report for the first quarter of 2019 on May 9, at 9.30 a.m. CET

BioArctic AB to publish the company’s Interim Report for the period January – March 2019 on Thursday, May 9, 2019 at 08:00 a.m. CET.

April 29, 2019
·
1 min read
Deals

Fusion Antibodies plc Director/PDMR Shareholding

Fusion Antibodies plc announces that Dr Paul Kerr, Chief Executive Officer of the Company, has purchased 1,290 ordinary shares in the Company at a price of 77 pence per Ordinary Share.

April 29, 2019
·
1 min read
Microbix to Present at Bloom Burton Conference

Healthcare Investor Conference in Toronto on April 30 & May 1

April 29, 2019
·
4 min read
Business

Charles B. Berde, MD, PhD, Joins Scientific Advisory Board of Akelos Inc., Biotechnology Company Developing Opioid Alternatives

Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain, adds Dr. Charles Berde to its Scientific Advisory Board.

April 29, 2019
·
4 min read
Policy

ViiV Submits NDA for Once-Per-Month HIV Injectable

The NDA was based on positive Phase III data that shows the once-a-month treatment is as effective as the daily standard of care.

April 29, 2019
·
2 min read
·
Alex Keown